An 86-year-old woman was admitted to our hospital in an emergent condition due to repeated vomiting and hematemesis. She had been diagnosed with diabetes mellitus at 64 years of age. She had an HbA1c level of 12.4 % with glimepiride (2 mg), pioglitazone (30 mg), and sitagliptin (100 mg), and her body mass index was 17.3 kg/m
2. Four days prior to her admission, glimepiride and pioglitazone had been exchanged for dapagliflozin (5 mg). The laboratory findings at admission were as follows: plasma glucose, 299 mg/dL; arterial blood gas, pH 7.093; HCO
3-, 8.1 mmol/L; and 3-hydroxybutyric acid, 15420
μmol/L. She was diagnosed with diabetic ketoacidosis (DKA), and continuous venous insulin infusion was started for treatment. Her excretion of urinary C-peptide was decreased (2.2
μg/day). She also had an acute myocardial infarction (AMI), and percutaneous coronary intervention was performed on the day of admission. Given these observations in the present case, physicians should carefully take into consideration the patients' pathological condition and lifestyle before prescribing novel selective inhibitors of sodium glucose co-transporter 2 (SGLT2 inhibitor).
View full abstract